Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines
Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.
You may also be interested in...
Drop in number of prescriptions dispensed for opioids contributed to minimal spending growth for retail prescription drugs in 2017, according to latest CMS National Health Expenditures Report.
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.